By contrast, once a stroke has occurred, the only approved drug for stroke therapy is intravenous recombinant tissue plasminogen activator (tPA), currently given to only 2–3% of stroke patients because of its limited time window for administration and the major risk for adverse effects. The gene discussed is PLAT; the disease is stroke disorder.